Skye Bioscience, Inc. (SKYE) is a San Diego–based, clinical-stage biotechnology company that once centered its story on nimacimab, an antibody targeting the CB1 receptor for obesity and metabolic disease. That story has changed dramatically: the company terminated its lead obesity program and has agreed to combine with U.K.-based Redx Pharma, pivoting toward a fibrosis-focused pipeline under a new entity expected to be named Fibrx Therapeutics. Against that backdrop, the question of whether SKYE can reach roughly $3.30 a share is less about a conventional analyst forecast than about whether a heavily discounted merger closes on its headline terms.
This is a fallback, deal-derived reference rather than an analyst price target. In an August 2026 filing, Skye disclosed a definitive agreement to acquire Redx Pharma through a scheme of arrangement. The agreement values Skye at approximately $14.5 million, subject to a $2 million floor. Dividing that headline equity value by the roughly 4.43 million shares outstanding after the 1-for-8 reverse stock split (effective August 24, 2026) produces a per-share reference near $3.27, rounded here to $3.30.
For context, a handful of pre-merger analyst targets remain on record — spanning roughly $16 to $168, with a mean near $61–$68 — but those were set while nimacimab was still Skye's lead program and before the Redx transaction and the reverse split were announced. They do not reflect the company's new strategy or the dilution embedded in the deal, so they are cited here for background only, never as the target.
SKYE closed near $0.80 on November 9, 2026, with a market capitalization of roughly $3.5 million. The stock's 52-week range spans about $0.50 to $12.72, underscoring extreme volatility. Reaching $3.30 would require a gain of more than 300%, a very large move.
The realistic path runs almost entirely through the merger. Legacy Skye shareholders would retain only about 5.38% of the combined company (potentially less if the valuation floor applies), while also receiving contingent value rights (CVRs) tied to the disposition of Skye's pre-merger assets. The deal is expected to close in the fourth quarter of 2026, subject to shareholder approvals, sanction by the High Court of England and Wales, Nasdaq listing approval, and completion of at least $67.9 million in financing.
The primary support is the Redx combination itself. The merged company would carry a fibrosis-focused pipeline led by RXC008, a potential first-in-class pan-ROCK inhibitor targeting fibrostenotic Crohn's disease, an indication with no approved therapies. The deal is backed by roughly $67.9–$72.9 million in concurrent equity financing, a separate Redx Series A round, an equity line of credit, and a warrant, which together aim to fund operations into 2029. Regaining Nasdaq bid-price compliance through the reverse split also removes a near-term delisting overhang.
The obstacles are substantial. Legacy Skye holders face heavy dilution, keeping only about 5.38% of the combined company. The transaction's $2 million valuation floor, if triggered by an unresolved adjustment, would imply roughly $0.45 per share on current shares outstanding — below the recent price. Skye has also disclosed substantial doubt about its ability to continue as a going concern without closing the Redx deal or securing new capital, and the transaction requires multiple approvals that could fail. Separately, nimacimab's monotherapy arm missed its primary endpoint in the CBeyond Phase 2a study, and the company has paused related research and development while winding down operations.
After the reverse split, the shares are thinly traded and highly volatile. The $1.00 level is significant as the Nasdaq minimum bid-price threshold Skye had been working to sustain. Below it, the 52-week low near $0.50 marks a key support zone; above it, any sustained recovery would first confront the post-split highs that top out near $12.72, leaving limited near-term technical anchors between the current price and $3.30.
Unlike a typical 12-month analyst price forecast, this target is tied to a near-term transaction. Investors should monitor the shareholder votes, the English court sanction of the scheme of arrangement, completion of the concurrent PIPE (private investment in public equity) financing, and Nasdaq listing approval. The outcome of any "Specified Adjustment" that could push Skye's valuation toward the $2 million floor, plus any updates on monetizing the legacy nimacimab and SBI-100 assets through the CVRs, will also matter.
For traders tracking volatile, event-driven names like SKYE, AI Daily Buy/Sell Signals offers a complementary tool. The platform uses artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals from changing market conditions, technical behavior, and AI-driven analysis. This can help traders discover opportunities, monitor existing positions, and spot shifting trends more efficiently than manual screening.
Whether SKYE can reach $3.30 is fundamentally a question about the Redx Pharma merger closing on its stated terms, since the target reflects Skye's $14.5 million deal valuation rather than an analyst forecast. The required move of more than 300% is very large, and the supportive merger structure is offset by severe dilution for legacy holders, a valuation floor that could value shares below the current price, and a going-concern warning. The stale pre-merger analyst targets only underscore how much the investment thesis has changed. Investors will be watching the deal's closing conditions and financing milestones most closely.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor indicates that over the last year, SKYE has been loosely correlated with ZURA. These tickers have moved in lockstep 37% of the time. This A.I.-generated data suggests there is some statistical probability that if SKYE jumps, then ZURA could also see price increases.
| Ticker / NAME | Correlation To SKYE | 1D Price Change % | ||
|---|---|---|---|---|
| SKYE | 100% | +9.54% | ||
| ZURA - SKYE | 37% Loosely correlated | +1.78% | ||
| ABEO - SKYE | 36% Loosely correlated | -6.31% | ||
| VKTX - SKYE | 34% Loosely correlated | -0.77% | ||
| ACAD - SKYE | 33% Loosely correlated | +0.49% | ||
| ABOS - SKYE | 30% Poorly correlated | N/A | ||
More | ||||